retatrutide clinical trials sign up How to Get in 2026 Retatrutide is a new type

In most cases, adults may qualify for GLP-1 weight loss medications with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as high blood pressure, type 2 diabetes, prediabetes, high cholesterol, sleep apnea, or cardiovascular disease

It is currently only available within clinical trial settings and is being evaluated for the treatment of obesity and type 2 diabetes

Pharmaceutical-grade peptide powders stored in freezers without auto-defrost functionality can maintain stability for three or more years confirmed, with potential longevity extending to ten years under optimal conditions

Larger peptides with post-translational modifications (like the fatty diacid moiety on retatrutide) are more susceptible to degradation than simpler sequences

If you notice any neck swelling, hoarseness, or difficulty swallowing while on semaglutide, contact your prescriber promptly